X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
+$0.06 today
- Market cap
- $302.26M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
Volume 1.12M
Average 0.40M
Returns on capital
X4 Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.5%
avg -12.1%
ROIC
-32.7%
avg -460.5%
ROA
-27.3%
avg -105.3%
Analysis
ROA is currently the strongest return metric at -27.3% versus its period average of -105.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David H. Kirske | Chief Financial Officer, Treasurer & Corporate Secretary | USD 722.33K | 72 | — | — |
Adam R. Craig | Executive Chair | USD 575.55K | 60 | 333.25K | 0.35% |
John Volpone | President & Chief Operating Officer | USD 532.99K | 51 | 265.31K | 0.28% |
Keith T. Flaherty | Founder & Member of Corporate Advisory Board | — | 55 | — | — |
Richard Peters | Founder | — | 64 | — | — |
Renato T. Skerlj | Founder | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$11,883.64
Sells
5
$462,964.22
Net Transaction Value
−$451,080.58
Net selling
Most Active
KIRSKE DAVID
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 16, 26Oct 16, 2026 | Craig Adam R Direct | Buy | $11.9K$11,883.64 |
| Oct 1, 26Oct 1, 2026 | KIRSKE DAVID Direct | Sell | $33.7K$33,658.33 |
| Aug 12, 26Aug 12, 2026 | Volpone John Direct | Sell | $109.2K$109,228.03 |
| Aug 12, 26Aug 12, 2026 | Craig Adam R Direct | Sell | $210.8K$210,829.30 |
| Jun 30, 26Jun 30, 2026 | KIRSKE DAVID Direct | Sell | $36.4K$36,428.21 |
| May 12, 26May 12, 2026 | KIRSKE DAVID Direct | Sell | $72.8K$72,820.36 |
Summary
Insiders reported 1 buys worth $11,883.64 and 5 sells worth $462,964.22 over the last 12 months. That adds up to net selling of $451,080.58. KIRSKE DAVID was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +71.7% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +71.7% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does X4 Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about XFOR's management, answered from reported figures.
Who manages XFOR?
X4 Pharmaceuticals, Inc. (XFOR) lists 6 active executives. The top listed executive is Adam R. Craig, Executive Chair.
Are XFOR insiders buying or selling?
Recent insider activity shows net buying of $25.18M.
Continue the stock analysis
Jump to another research area for this company.